The Metabolic Syndrome and Carotid Intima-Media Thickness in Relation to the Parathyroid Hormone to 25-OH-D(3) Ratio in a General Population by Richart, Tom et al.
102   JANUARY 2011 | VOLUME 24 NUMBER 1 | 102-109 | AMERICAN JOURNAL OF HYPERTENSION
nature publishing groupORIGINAL CONTRIBUTIONS
Active vitamin D3 (1,25-(OH)2-D3; calcitriol) and parathyroid 
hormone (PTH) are calciotropic hormones that interactively 
control renal calcium excretion and keep circulating calcium 
levels within physiological limits by balancing calcium fixa-
tion and mobilization in bone tissue against gastrointestinal 
uptake. The precursor of active vitamin D, cholecalciferol, is 
generated in the skin from 7-deoxy-cholesterol by UV irradia-
tion or is gastrointestinally absorbed from food or medicinal 
supplements.1 The 25-hydroxylase activity in the liver con-
verts cholecalciferol to 25-OH-D3 (calcidiol), the commonly 
measured biomarker of vitamin D status. The enzymatic 
1α-hydroxylase activity, which in the proximal renal tubuli 
converts  circulating 25-OH-D3 to the hormonally active 
1,25-(OH)2-D3 (calcitriol), is central to the endocrine function 
of calcitriol and PTH as modulators of calcium homeostasis.2 
The interactive effects of these hormones also regulate calcium 
fluxes across cell membranes, hereby modulating pancreatic 
islet cell insulin secretion,3 target cell insulin sensitivity,3 blood 
pressure control,2 and carotid artery calcification.4
Population studies showed positive associations of circulat-
ing PTH and negative associations of 25-OH-D3 with carotid 
intima-media thickness (CIMT),4–6 blood pressure,2,6,7  insulin 
resistance,8,9 and fasting blood glucose.8,9 A high calcium 
intake lowers PTH10,11 and decreases the risk of cardiovascular 
and metabolic diseases.12 Furthermore, when habitual  calcium 
intake is low, calcium appears to shift from bone into the arterial 
wall, the so-called “calcium paradox.”13 To our  knowledge, the 
interactive effects of habitual calcium intake, PTH and 25-OH-
D3 on the prevalence of the metabolic syndrome (MS) and 
its components and on arterial phenotypes have not yet been 
simultaneously assessed at the level of a  general  population. 
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BACKGROUND
Parathyroid hormone (PTH) and vitamin D interactively regulate 
calcium fluxes across membranes, and thereby modulate 
insulin sensitivity, blood pressure, and arterial calcification. We 
hypothesized that lower calcium intake as reflected by circulating 
PTH and 25-OH-D3 might be associated with the metabolic 
syndrome (MS) and arterial calcification.
METHODS
In a random population sample (n = 542; 50.5% women; mean 
age, 49.8 ± 13.1 years), we measured MS prevalence (International 
Diabetes Federation (IDF) and American Heart Association (AHA) 
criteria), PTH and 25-OH-D3, serum and 24-h urinary calcium, 
MS components, carotid intima-media thickness (CIMT), and 
calcium intake from dairy products. We assessed associations in 
multivariable-adjusted analyses, using linear and logistic regressions.
RESULTS
The prevalence of MS was 21.0% (IDF criteria) and 23.6% 
(AHA criteria). MS prevalence, blood pressure, waist circumference, 
body mass index, fasting blood glucose, insulin and triglycerides, 
and CIMT increased (P ≤ 0.042) across quartiles of the PTH/25-OH-D3 
ratio, whereas serum and 24-h urinary calcium decreased (P ≤ 0.029). 
Waist circumference and fasting blood glucose decreased across 
quartiles of habitual calcium intake (P ≤ 0.04). In models that included 
MS (IDF) and PTH/25-OH-D3, the regression coefficients relating 
CIMT to PTH/25-OH-D3 ratio and MS were +51 μm (P = 0.013) and 
+19 μm (P = 0.45), respectively. Multivariable-adjusted analyses 
were confirmatory.
CONCLUSIONS
MS prevalence and CIMT were positively associated with PTH/25-OH-D3. 
CIMT was not associated with MS. Prospective studies and intervention 
trials should address the causality of these associations.
Keywords: 25-OH-D3; blood pressure; calcium; hypertension; insulin 
resistance; intima-media thickness; metabolic syndrome; PTH; vitamin D
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We hypothesized that an increased PTH/25-OH-D3 ratio 
 promotes an inward calcium flux in target cells that are involved 
in glucose metabolism and arterial calcification, and that these 
effects are more pronounced in individuals with low habitual 
 calcium intake. To address our working hypothesis, we assessed 
in a general population habitual calcium intake, glucose and 
 calcium metabolism, and CIMT.
METHODS
Study population. The Ethics Committee of the University of 
Leuven approved the protocol of the FLEMENGHO (Flemish 
Study on Environment, Genes and Health Outcomes). All 
subjects gave informed written consent. From August 1985 
until November 1990, a random sample of the households 
living in a geographically defined area of Northern Belgium 
was invited, with the goal of recruiting equal numbers of par-
ticipants in each of the six subgroups defined by sex and age 
(20–39, 40–59, and ≥60 years) that would go through repeated 
examination cycles. The study population included 2,310 sub-
jects. The  participation rate among the subjects contacted 
was 66.1%. The random  subsample for the present analysis, 
included 550 subjects invited during a specific phase of the 
study, from which we excluded eight patients with  diabetes 
mellitus. At  enrolment, blood pressure was measured five 
times consecutively by trained observers at each of two home 
visits at an interval of 3–4 weeks. Thus, the study subjects 
were familiarized with the settings of the study and the study 
team, the same observer measuring their blood pressure at the 
baseline and the follow-up examinations in most cases. The 
diagnosis of hypertension therefore complied with current 
guidelines, which  recommend blood pressure measurement 
at repeated occasions to ascertain the diagnosis of an elevated 
blood pressure.
Clinical measurements. For at least 3 h before being examined, 
the participants were asked to refrain from heavy exercise, 
smoking, alcohol, or caffeine-containing beverages. Trained 
nurses administered a standardized and validated question-
naire to collect information about each subject’s medical his-
tory, smoking and drinking habits, dietary intake of calcium, 
and the use of medications. The questionnaire also provided 
detailed information on the total number of hours spent 
in sports and occupational activities, including attending 
school for younger people. With the use of published tables, 
we  estimated the energy spent in physical activity from body 
weight, time devoted to work and sports, and types of physical 
activity.14 We estimated dietary calcium intake from the use of 
dairy products and the calcium content as listed in the Dutch 
food tables. For statistical analysis, we expressed alcohol intake 
and current smoking as a dichotomous variable.
After the subjects had rested for at least 5 min in the sitting 
position, the nurses measured blood pressure five times con-
secutively with a standard mercury sphygmomanometer by 
auscultation of the Korotkoff sounds. For participants with an 
arm circumference of <32 cm, a standard cuff, with an inflat-
able bladder with a length of 22 cm and a width of 12 cm, was 
used to measure blood pressure. In participants with a greater 
arm circumference, cuffs with a 35 × 15 cm bladder were 
applied. For analysis, we averaged the five blood pressure read-
ings. Body mass index was weight in kilograms divided by the 
square of height in meters. The waist-to-hip ratio, determined 
by means of a tape measure, was the ratio of the smallest 
 circumference at the waist to the largest circumference at the 
hip. The nurses measured the skinfold at the mid portion of the 
triceps by means of a Harpenden Caliper (Baty, West Sussex, 
UK) providing a constant pressure of 0.01 kg/mm2 (0.098 N/
mm2) at all openings of the 90 mm2 anvils.
The MS components were as follows: elevated blood pres-
sure, defined as a blood pressure of at least 130 mm Hg systo-
lic or 80 mm Hg diastolic or the use of antihypertensive drugs; 
central obesity, defined as a waist circumference of ≥88 cm or 
≥102 cm in women and men, respectively; serum triglycer-
ides of ≥150 mg/dl; high-density lipoprotein-cholesterol <50 
or <40 mg/dl in women and men, respectively; and a fasting 
blood glucose of ≥100 mg/dl. The American Heart Association 
(AHA)15 recommends that the MS be identified as the pres-
ence of three or more components. The International Diabetes 
Federation (IDF)16 defines the presence of the MS as an 
 elevated waist circumference and the presence of two or more 
other components.
Biochemical measurements. The participants collected a timed 
24-h urine sample for the measurement. Blood samples were 
collected into chilled EDTA-containing tubes after an overnight 
fast, centrifuged and divided in aliquots within 30 min after 
venipuncture. Total and high-density lipoprotein- cholesterol 
and triglycerides in serum, blood glucose, and serum and 
urinary creatinine were measured by automated enzymatic 
methods. Serum insulin was determined by immunoassay, 
and calcium in serum and urine by a complexometric titration 
method.17 We computed the homeostasis model assessment of 
insulin resistance index as (fasting glucose × fasting insulin)/65. 
Plasma intact PTH was measured by an immunoradiometric 
assay and plasma 25-OH-D3 by a competitive protein bind-
ing assay (Medgenix, Fleurus, Belgium). The PTH/25-OH-D3 
ratio was PTH in pg/ml divided by 25-OH-D3 in ng/ml.
Arterial phenotypes. The same observer (E.J.B.) performed all 
measurements of CIMT, using a wall-tracking ultrasound sys-
tem with a 7.5 MHz probe. She recorded IMT at the right com-
mon carotid artery 2 cm proximal of the bulb, and recorded 
blood pressure for off-line calibration of distension curves. The 
same operator (E.J.B.) measured off-line the distances from the 
adventitia-media boundary of the near wall to the lumen-in-
tima and media-adventitia interfaces of the far wall. The IMT 
was computed as the mean difference between these distances 
measured over three separate intervals of 5.2 s, which on average 
included 15 heart cycles. The intraobserver intrasession coef-
ficients of variability amounted to (± s.d.) 5.2 ± 1.7%.18 During 
the examination and postprocessing of ultrasonographic data, 
the observer was blinded to the biochemical  profiles used to 
classify subjects according to their MS status.
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Statistical analysis. For database management and  statistical 
analysis, we used SAS software, version 9.2 with the JMP 
add-on, version 7 (SAS Institute, Cary, NC). Measurements 
with a skewed distribution were normalized by a  logarithmic 
transformation. The geometric mean and the 5th–95th per-
centile interval represented the central tendency and spread 
of logarithmically transformed variables. We compared 
means and proportions by the standard normal z test and 
Fisher’s exact test, respectively. We used the PROC GLM 
procedure, as implemented in the SAS package to compare 
means across quartiles of the PTH/25-OH-D3 ratio. We 
searched for  covariables of the outcome variables of interest, 
using stepwise multiple linear regression, with the P value 
for independent variables to enter and stay in the model 
set at 0.15. We used logistic regression to evaluate associa-
tions of the MS defined according to AHA/IDF criteria with 
covariables. We expressed effect sizes with 95% confidence 
interval (CI) in regression analysis for a 1-s.d. increase in the 
 explanatory variable.
RESULTS
Characteristics of the participants
The participants included 272 women and 270 men. There 
were no differences between women and men in age (mean ± 
s.d., 49.3 ± 12.8 vs. 50.2 ± 13.3 years, respectively; P = 0.38); 
in the circulating levels of PTH (geometric mean (5th–95th 
percentile interval), 23.22 pg/ml (12.60–43.59) vs. 22.56 pg/ ml 
(12.70–38.95); P = 0.39) and 25-OH-D3 (29.4 ng/ml (27.8–
30.9) vs. 28.6 ng/ml (27.24–29.93); P = 0.45), or in the PTH/25-
OH-D3 ratio (0.83 (0.39–1.66) vs. 0.81 (0.41–1.68); P = 0.79). 
Among women, 148 (54.4%) and 124 (45.6%) were pre- or 
postmenopausal, respectively. Among women and men, 83 
(30.7%) and 87 (33.1%) were smokers; 22 women (8.2%) and 
91 men (34.6%) reported alcohol intake. In smokers, median 
tobacco use was 15 cigarettes per day (interquartile range, 
10–21). In drinkers, the median alcohol consumption was 20 g 
per day (interquartile range, 10–30). At the time of question-
ing, 89 (16.4%) of the participants reported intake of antihy-
pertensive medication.
The MS and its components across quartiles  
of calcium intake from dairy sources
The median daily intake of calcium from dairy sources was 
128 mg/day (interquartile range, 69–252 mg/day). Across 
increasing quartiles of calcium intake, waist circumference 
decreased from 90.0 to 85.7 cm and fasting glucose from 
92.3 to 87.0 mg/dl (P for trend, <0.02 and <0.04, respec-
tively). Lower calcium intake was also associated with 
increased systolic (Q1–Q4, 128.5–123.6 mm Hg, P = 0.018) 
and diastolic blood pressure (Q1–Q4, 79.8–76.8 mm Hg, P = 
0.024), but this trend did not reach significance for CIMT 
(Q1–Q4, 798–841 μm, P = 0.24), for fasting insulin (Q1–Q4, 
5.98–7.27 μIU/ml, P = 0.32) or triglycerides (Q1–Q4, 
180.7–169.1 mg/dl, P = 0.17). The prevalence of the MS did 
not decrease significantly across quartiles of calcium intake 
(Q1–Q4, 22.6–21.2%, P = 0.88).
The MS and its components across quartiles  
of the PTH/25-OH-D3 ratio
Table 1 lists the demographic characteristics of the  participants 
by quartiles of the PTH/25-OH-D3 ratio. Across quartiles, there 
were significant increases in systolic and diastolic blood pres-
sure (P = 0.0048 and 0.014, respectively), body mass index (P = 
0.0005), waist circumference (P < 0.0001), waist-to-hip ratio 
(P = 0.048), fasting blood glucose (P = 0.011), fasting insulin 
(P = 0.0005), homeostasis model assessment of insulin resist-
ance index (P = 0.0003), serum triglycerides (P = 0.027), and 
the CIMT (P = 0.042). On the other hand, serum total calcium 
(P = 0.0003) and the 24-h urinary calcium excretion decreased 
(P = 0.0292) across quartiles of the PTH/25-OH-D3 ratio.
The prevalence of the MS increased across quartiles of 
the PTH/25-OH-D3 ratio, irrespective of whether the IDF 
(P = 0.0005) or AHA (P = 0.0513) definition was applied 
(Figure 1a). Of the dichotomized components of the MS, waist 
circumference (P = 0.0019), fasting blood glucose (P = 0.024), 
and serum triglycerides (P = 0.060), but not the prevalence of 
hypertension (P = 0.30) increased across the PTH/25-OH-D3 
quartiles (Figure 1b). There was no association between serum 
high-density lipoprotein-cholesterol and the PTH/25-OH-D3 
ratio (P = 0.32).
Odds of the MS in relation to calciotropic hormones
Figure 2 shows the odds ratios (ORs) for the MS associated 
with 1-s.d. increases (3.02 units) in PTH/25-OH-D3 and 
the components of this ratio. The OR for the MS  according 
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Figure 1 |  Prevalence of the (a) metabolic syndrome and (b) its components 
across quartiles of the ratio of parathyroid hormone (in pg/ml) to 25-OH-D3 
(in ng/ml) ratio. P values are for the trends across quartiles of this ratio. 
Numbers above the bars refer to the subjects contributing to the numerator 
to compute the prevalence. (a) IDF and AHA refer to the metabolic syndrome 
according to the International Diabetes Federation16 and American Heart 
Association15 definitions, respectively. (b) WC, waist circumference; FG, 
fasting glucose; BP, blood pressure; TG, serum triglycerides; HDL, high-density 
lipoprotein. The components of the metabolic syndrome were dichotomized 
according to IDF as described in the Methods.
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to the IDF definition was 0.19 (95% CI, 0.07–0.55; P = 
0.0021) for 25-OH-D3, and 1.78 (CI, 1.15–2.84; P = 0.012) 
for the PTH/25-OH-D3 ratio, whereas the OR of 1.40 (CI, 
0.84–2.33; P = 0.18) for PTH did not reach statistical signifi-
cance (Figure 2). The findings for the MS according to the 
AHA definition were similar, but only the OR for 25-OH-D3 
reached statistical significance (Figure 2). Adjustment of 
these ORs for lifestyle factors, such as smoking or drinking 
alcohol, did not materially alter the estimates as shown in 
Figure 2.
Association of the MS components with calciotropic  
hormones
Table 2 lists the standardized regression coefficients express-
ing the changes in the MS components and other biomarkers 
associated with 1-s.d. increments (3.02 units) in 25-OH-D3, 
PTH (with and without mutual adjustment) and the PTH/25-
OH-D3 ratio. Blood pressure, waist circumference, serum 
triglycerides, fasting insulin, and the homeostasis model 
assessment of insulin resistance index increased with the 
PTH/25-OH-D3 ratio. Serum calcium and the 24-h urinary 
Table 1 | Characteristics of participants by quartiles of the PTH/25-OH-D3 ratio
Low Medium-low Medium-high High P
Quartile boundaries 0.16–0.56 0.57–0.79 0.80–1.17 1.18–8.66
Number 136 135 136 135
Mean ± s.d. of characteristic
 Age (years) 47.1 ± 12.4 49.7 ± 12.3 49.6 ± 13.8 52.7 ± 13.2 0.0007
 Systolic pressure (mm Hg) 123.6 ± 16.2 124.7 ± 16.1 127.1 ± 16.9 128.9 ± 18.2 0.0048
 Diastolic pressure (mm Hg) 76.9 ± 9.8 78.4 ± 10.1 79.9 ± 10.3 79.5 ± 10.4 0.014
 Pulse rate (beats/min) 69.8 ± 9.6 70.6 ± 10.7 70.2 ± 9.5 71.3 ± 10.6 0.29
 Body mass index (kg/m2) 24.7 ± 3.5 26.1 ± 4.4 26.4 ± 4.1 26.4 ± 4.2 0.0005
 Triceps skinfold thickness (cm) 1.55 ± 0.68 1.63 ± 0.66 1.71 ± 0.69 1.66 ± 0.82 0.11
 Waist circumference (cm) 85.2 ± 11.4 88.3 ± 12.5 88.5 ± 11.8 91.5 ± 12.6 <0.0001
 Waist-to-hip ratio 0.85 ± 0.09 0.85 ± 0.09 0.85 ± 0.10 0.87 ± 0.09 0.048
 Blood glucose (mg/dl) 88.4 ± 11.3 87.3 ± 9.1 88.9 ± 10.4 92.7 ± 23.4 0.011
 HDL-cholesterol (mg/dl) 51.1 ± 12.6 52.0 ± 15.3 50.5 ± 13.5 49.9 ± 15.4 0.34
 Serum calcium (mg/dl) 9.40 ± 0.36 9.36 ± 0.40 9.28 ± 0.40 9.24 ± 0.40 0.0003
 24-h Urinary calcium (mg) 175 ± 81 179 ± 88 161 ± 79 149 ± 93 0.029
 24-h Urinary sodium (g) 4.47 ± 1.79 4.14 ± 1.40 4.18 ± 1.36 4.07 ± 1.41 0.21
 24-h Urinary potassium (g) 2.85 ± 1.11 2.69 ± 0.80 2.86 ± 1.12 2.72 ± 1.01 0.55
 24-h Na+/K+ ratio 1.66 ± 0.60 1.63 ± 0.58 1.58 ± 0.55 1.63 ± 0.61 0.69
 Carotid IMT (μm) 814 ± 223 820 ± 183 839 ± 203 880 ± 196 0.042
Geometric mean (5th–95th percentile interval)
 Insulin (μIU/ml) 5.98 (2.48–14.40) 5.98 (2.48–14.40) 7.41 (2.83–19.34) 7.78 (2.85–21.26) 0.0005
 Dietary calcium intake (mg/day)a 183.6 (151.3–215.8) 183.6 (151.3–215.8) 178.4 (156.8–199.9) 185.2 (155.1–215.4) 0.78
 PTH (pg/ml) 14.78 (12.73–18.20) 20.29 (16.84–25.04) 23.86 (19.30–29.60) 31.32 (24.02–41.60) <0.0001
 25-hydroxyvitamin-D3 (ng/ml) 32.6 (30.7–34.5) 32.6 (30.7–34.5) 27.4 (25.9–29.0) 20.7 (19.2–22.2) <0.0001
 HOMA (units) 1.50 (0.57–3.96) 1.50 (0.57–3.96) 1.74 (0.59–5.17) 1.89 (0.57–6.31) 0.0003
 Triglycerides (mg/dl) 145.0 (56.9–390.2) 145.0 (56.9–390.2) 153.4 (44.7–526.2) 173.2 (62.1–483.1) 0.022
 Daily energy expenditure (kcal) 1,297 (420–2,605) 1,297 (420–2,605) 1,393 (449–2,873) 1,204 (232–2,637) 0.39
Number (%) with characteristic
 Female sex 66 (48.5) 66 (48.5) 70 (51.5) 69 (51.1) 0.67
 Smokers 55 (40.4) 55 (40.4) 40 (29.4) 36 (26.7) 0.018
 Drinkers 29 (21.3) 29 (21.3) 28 (20.6) 29 (21.5) 0.95
 Diuretics 4 (2.9) 4 (2.9) 17 (12.5) 13 (9.6) 0.0036
 β-Blockers 8 (5.9) 8 (5.9) 18 (13.2) 18 (13.3) 0.0051
 Other antihypertensive drugs 11 (8.1) 11 (8.1) 11 (8.1) 14 (10.5) 0.48
P values are for trend across quartiles.
HDL, high-density lipoprotein; HOMA, homeostasis model assessment of insulin resistance; IMT, intima-media thickness; PTH, parathyroid hormone.
aIntake from dairy products.
106   JANUARY 2011 | VOLUME 24 NUMBER 1 | AMERICAN JOURNAL OF HYPERTENSION
ORIGINAL CONTRIBUTIONS MS, Carotid IMT, and PTH/25-OH-D3
calcium excretion decreased with higher PTH/25-OH-D3 
ratio.
Association of the CIMT with calciotropic hormones and MS
CIMT increased with higher PTH/25-OH-D3 ratio and higher 
PTH, but was not significantly associated with 25-OH-D3 
(Table 2). The association between CIMT and MS accord-
ing to the IDF definition16 was not significant (24 μm; CI, 
−23 to 71 μm; P = 0.28). Next, to estimate the independent 
contributions of the MS and the calciotropic hormones to 
the variance of CIMT, we constructed models that included 
the MS according to the IDF definition16 and either PTH, 
25-OH-D3, or PTH/25-OH-D3. The partial regression coeffi-
cients for the PTH/25-OH-D3 ratio (51 μm; CI, 11–91 μm; P = 
0.013) and PTH (67 μm/pmol/l; CI, 24–111 μm; P = 0.0027) 
were significant, whereas this was not the case for the regres-
sion coefficients for the MS in models including either the 
PTH/25-OH-D3 ratio (19 μm; CI, −30 to 68 μm; P = 0.45) or 
PTH (19 μm; CI, −29 to 69 μm; P = 0.43).
Multivariable-adjusted analyses
Figure 3 illustrates the prevalence of the MS according to the 
IDF definition (Figure 3a), CIMT (Figure 3b), fasting blood 
glucose (Figure 3c), and the 24-h urinary calcium excretion 
(Figure 3d) as a function of the cross-classification by quar-
tiles of PTH and 25-OH-D3. The analyses were adjusted for 
sex, age, lifestyle (current smoking and use of alcohol), and 
intake of antihypertensive medication. With increasing levels 
of PTH and decreasing levels of 25-OH-D3, we noted increases 
in the prevalence of the MS, fasting blood glucose, and CIMT, 
whereas the opposite was the case for the 24-h urinary calcium 
excretion.
Sensitivity analyses
Exclusion of postmenopausal women on hormonal replace-
ment therapy (n = 7 of 124; 5.6%) from the analyses, and addi-
tional adjustment for ever smoking, physical activity, or 24-h 
urinary Na, K, and/or the urinary Na/K ratio did not materi-
ally alter our results. 25-OH-D3 levels were not significantly 
related to the level of physical activity (β = 0.0016; P = 0.16).
DISCUSSION
The key findings of our population-based study are the sig-
nificant positive associations of the PTH/25-OH-D3 ratio 
with the prevalence of the MS and its components and CIMT. 
Furthermore, in models with CIMT as the dependent  variable, 
Table 2 | Parameter estimates for a 1-s.d. increase in 25-OH-D3, PTH, and the PTH/25-OH-D3 ratio
Characteristic 25-OH-D3
25-OH-D3  
adjusted for PTH PTH
PTH adjusted  
for 25-OH-D3 PTH/25-OH-D3
Systolic pressure 
(mm Hg)
−12.19 (−19.51 to −4.86)† −12.06 (−19.38 to −4.75)† 1.59 (−1.73 to 4.90) 1.37 (−1.92 to 4.65) 3.26 (0.29 to 6.24)*
Diastolic pressure 
(mm Hg)
−4.17 (−8.61 to 0.28) −4.05 (−8.49 to 0.38) 1.36 (−0.64 to 3.36) 1.28 (−0.71 to 3.28) 1.78 (−0.02 to 3.57)
Waist  
circumference (cm)
−10.53 (−15.79 to −5.25)‡ −10.14 (−15.36 to −4.93)‡ 4.31 (1.94 to 6.68)‡ 4.12 (1.78 to 6.46) 5.19 (3.08 to 7.30)‡
Blood  
glucose (mg/dl)
−10.05 (−16.45 to −3.65)* −9.91 (−16.31 to −3.50)* 1.78 (−1.12 to 4.66) 1.59 (−1.28 to 4.46) 3.07 (0.48 to 5.66)†
HDL-cholesterol 
(mg/dl)
7.87 (1.73 to 14.01)* 7.85 (1.70 to 14.01)* −0.38 (−3.11 to 1.41) −0.19 (−2.96 to 2.57) −1.55 (−4.04 to 0.94)
Serum  
calcium (mg/dl)
0.16 (−0.02 to 0.33) 0.15 (−0.026 to 0.319) −0.13 (−0.21 to −0.05)‡ −0.13 (−0.21 to −0.01)‡ −0.13 (−0.20 to −0.06)‡
24-h Urinary 
calcium (mg)
4.27 (0.12 to 8.42)* 4.11 (−0.03 to 8.24)* −1.52 (−3.29 to 0.25) −1.43 (−3.20 to 0.33) −1.88 (−3.47 to −0.28)*
Triglycerides  
(mg/dl)
−0.72 (−0.57 to −0.91)† −0.72 (−0.56 to −0.94)† 1.06 (−0.96 to 1.18) 1.06 (−0.96 to 1.17) 1.11 (1.01 to 1.22)*
Insulin (μIU/ml) −0.85 (−0.96 to 1.05) −0.86 (−0.69 to 1.06) 1.16 (1.05 to 1.27)† 1.15 (1.05 to 1.27)† 1.16 (1.06 to 1.26)‡
HOMA index (units) −0.11 (−0.22 to −0.01)* −0.11 (−0.21 to 0.01) 0.07 (0.02 to 0.12)† 0.07 (0.02 to 0.12)† 0.08 (0.03 to 0.12)‡
CIMT (μm) 30 (−74 to 134) 33 (−69 to 136) 68 (24 to 112)† 68 (25 to 112)† 52 (12 to 93)†
Estimates express the change (95% confidence interval) in the dependent variable associated with a 1-s.d. increase in the explanatory variable (25-OH-D3: 11.9 ng/ml; PTH: 7.54 pg/ml).
CIMT, carotid intima-media thickness; HDL, high-density lipoprotein; HOMA, homeostasis model assessment of insulin resistance; PTH, parathyroid hormone.
Significance of the effect sizes: *P ≤ 0.05, †P ≤ 0.01, and ‡P ≤ 0.001.
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Figure 2 | Odds ratios for the metabolic syndrome (plotted along the 
horizontal axis) associated with 1-s.d. increases in the ratio of PTH (in pg/ml) 
to 25-OH-D3 (in ng/ml). AHA, American Heart Association; IDF, International 
Diabetes Federation; MS, metabolic syndrome; PTH, parathyroid hormone.
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the PTH/25-OH-D3-ratio remained significant, whereas the 
 presence of the MS did not. Analyses adjusted for sex, age, 
and lifestyle variables were confirmatory. Furthermore, higher 
calcium intake was negatively associated with waist circumfer-
ence, fasting blood glucose, and systolic and diastolic blood 
pressures. The novel aspect of our study lies in the simultane-
ous assessment of the PTH/25-OH-D3 ratio, the prevalence of 
the MS, its components, and CIMT in a general population. By 
and large, our current findings emphasize the role of calcio-
tropic hormones and calcium homeostasis in the pathogenesis 
of the MS and arterial calcification.
Our current findings are in keeping with other epidemiologic 
studies, in which either PTH,9,19 25-OH-D3,
12 or both20 were 
measured. In the National Health Examination and Nutrition 
Survey (NHANES III), in adjusted analyses, the prevalence 
of hypertension (OR, 1.30), obesity (OR, 2.29), and elevated 
serum triglycerides (OR, 1.47) was significantly higher in the 
bottom than in the top quartile of 25-OH-D3 (P < 0.001 for 
all).21 Similarly, in a Dutch population survey, the prevalence 
of hypertension was higher in the top vs. lowest quartile of 
PTH (OR, 2.00; 95% CI 1.31–3.06).22 Our results indicate that 
the risk of MS, related to the PTH/25-OH-D3 ratio, was mainly 
driven by 25-OH-D3.
In our current population study, lower calcium intake was 
associated with increased measures of central obesity and 
 fasting blood glucose. This is in line with the NHANES III 
findings, where the odds of being in the top quartile of body 
fat content were 0.16 for the top quartile (P < 0.001) with the 
bottom quartile of habitual calcium intake used as  reference.23 
Along similar lines, the DASH (Dietary Approaches to 
Stop Hypertension) diet reduced PTH by 0.26 pmol/l in 
healthy adults without a change in urinary calcium excretion 
(P < 0.05).11
The currently available evidence on the association of car-
diovascular risk factors with low 25-OH-D3,
8,12,24 high PTH 
levels,9,19 or both20 encompasses hypertension,2,24 obesity,19 
the MS,9,12,19,20 and diabetes mellitus.8 Some studies reported 
an inverse relationship between 25-OH-D3 and blood pres-
sure after adjustment for PTH,25,26 whereas others reported 
no relationship between blood pressure and 25-OH-D3 after 
adjustment for PTH.22,27 Our point of view is that express-
ing the physiologic interaction between PTH and 25-OH-D3 
as a ratio instead of by mutual adjustment22,25–27 for both 
calciotropic hormones sheds more clarity on the associations 
of these hormones with the MS, its components, and arterial 
calcification. Furthermore, calciotropic hormone ratios can 
provide additional information over and beyond their compo-
nents in inflammatory disease28 and in other fields.29
The multiple correlations between PTH, vitamin D,  calcium, 
obesity, and cardiometabolic and vascular risk markers can 
89.5
87.4
88.8
88.1
90.3
PTH1
2
3
41
2
3
4
Fasting glucose
(mg/dl)
PTH25-OH-D3 25-OH-D3
25-OH-D325-OH-D3
1
2
3
4
1
2
3
4
34
10
26
18
42
IDF MS+
(%)
PTH1
2
3
41
2
3
4
PTH4
3
2
1
3
4
2
1
16.8
15.2
16
17.6
Calcium excretion
(mg/24h)
850
830
810
870
790
Carotid IMT
 (μm)
ba
dc
Figure 3 | Prevalence of the (a) metabolic syndrome, (b) thickness of the carotid intima-media, (c) fasting blood glucose, and (d) 24-h urinary calcium excretion 
across quartiles of parathyroid hormone (PTH) and 25-OH-D3 (VD). The analyses were adjusted for sex, age, body mass index, smoking, alcohol intake, and the 
use of antihypertensive drugs. IDF, International Diabetes Federation; IMT, intima-media thickness; MS, metabolic syndrome; PTH, parathyroid hormone.
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be explained by several mechanisms. Obesity is  associated 
with increased PTH and hypovitaminosis D in the general 
population,20 whereas increased habitual calcium intake 
decreases the risk for obesity and cardiometabolic disease12,19 
and suppresses PTH secretion in healthy individuals.10 On the 
other hand, in patients with early hyperparathyroidism devoid 
of hypertension and renal disease, parathyroidectomy does 
not significantly change CIMT.30 Increased renal activation of 
25-OH-D3 to the active hormonal form inhibits the activity of 
the renin–angiotensin–aldosterone system.2 Supplementation 
with cholecalciferol or UV-B exposure increases 25-OH-D3 
and decreases blood pressure.2 Deficiencies in 25-OH-D3 
are associated with insulin resistance and decreased insulin 
secretion.3 In vitamin D–deficient patients, calcium supple-
mentation improves glucose intolerance,31 whereas vitamin 
D supplementation does not.9,32,33 Oral vitamin D supple-
mentation does not have an effect on weight loss in over-
weight or obese subjects.34 Production of 25-OH-D3 from 
orally absorbed vitamin D precursors, as opposed to endog-
enously produced precursors in the skin, is not controlled 
by internal feedback mechanisms, which might partially 
account for the lack of effect.2 Abdominal obesity, a princi-
pal component in the current definition of the MS,16 had the 
strongest association with the PTH/25-OH-D3 ratio at all 
ages, whereas measures of subcutaneous fat (triceps skinfold 
thickness) were not associated with this ratio in our popula-
tion (data not shown). Fat tissue is considered as a reservoir 
for vitamin D precursors, the amount and distribution of fat 
tissue is altered in obese individuals. Indeed, concentrations of 
25-OH-D3 in biopsies of subcutaneous fat tissue from obese 
adults were inversely related to the degree of overweight, and 
positively to the concentration of circulating 25-OH-D3.
35 
Furthermore, inflammatory cytokines released from abdomi-
nal adipose tissue further decrease the amount of circulating 
precursors by promoting extrarenal activation of 25-OH-D3 
by tissue macrophages.36 In obese children, both PTH and 
25-OH-D3 levels normalize after weight loss, in parallel with 
a decrease in insulin resistance,37 suggesting reversibility at 
young age. Furthermore, the extrarenal activation of circulat-
ing 25-OH-D3, by activated macrophages in the vascular wall, 
opens calcium channels on vascular smooth muscle cells and 
thus accelerates arterial  calcification.2 This local activation 
to the active hormonal form partially underlies the lowered 
 circulating concentration of the precursor, 25-OH-D3.
2
The results of this study must be interpreted according to 
its strengths and weaknesses. We did not assess markers of 
inflammation. Inflammation is often considered to accelerate 
the pathogenesis of the MS and some of its components. Under 
inflammatory conditions, tissue macrophages can locally 
activate circulating 25-OH-D3 to the active hormone, which 
opens calcium channels and promotes calcification in vascu-
lar smooth muscle cells.2 The production of vitamin D precur-
sors in the skin declines with age, and is confounded by several 
factors including geographic location, skin color, habitual 
solar exposure, use of sunscreen, and dietary intake of animal 
foodstuffs and supplements.38–40 In the current study, we did 
not measure skin color, but adjusting PTH and/or 25-OH-D3 
 values for the hours of sun in the month of blood sampling did 
not substantially change the results (data not shown). We did 
not measure the excretion of the major metabolite of vitamin D 
(calcitroic acid), which might better quantify the uncontrolled 
extrarenal activation of circulating 25-OH-D3. Furthermore, 
the cross-sectional approach used in this study does not allow 
inference of causality. Finally, we did not assess genetic varia-
tion in the vitamin D receptor, which is associated with serum 
total calcium,41 PTH,42 elevated fasting glucose,43 early-onset 
type 2 diabetes,44 and the prevalence of the MS.45,46
In conclusion, using an integrated approach, we showed in a 
general population that an increased ratio of PTH/25-OH-D3 
is associated with increased abdominal obesity, impaired 
glucose tolerance, an increased prevalence of the MS and its 
components, and increased CIMT. However, CIMT was not 
associated with MS. These findings are novel and in keeping 
with observations in obese children, in whom impaired glu-
cose tolerance was a better predictor of CIMT than different 
definitions of the MS. Dysregulation of calcium homeostasis 
might therefore be a common mechanism leading to both the 
MS and arterial calcification. Prospective and intervention 
 studies should address the causality of these relationships. 
When addressing multiple risk factors in patients affected by 
the MS, attention should also go to appropriate dietary  calcium 
intake and sufficient outdoor activity with responsible solar 
exposure. Future studies are needed to clarify the long-term 
effects of dietary calcium intake and vitamin D obtained from 
sunlight or external sources in the pathogenesis of cardio-
metabolic disease and the prevention of the MS.
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